IMS Health RWES: The Future of Real-World Insights in Cancer
-
Upload
imshealthrwes -
Category
Healthcare
-
view
606 -
download
0
Transcript of IMS Health RWES: The Future of Real-World Insights in Cancer
REAL-WORLD EVIDENCE SOLUTIONS
An RWE ecosystem for commercial and clinical success
MEET THE FUTURE OF REAL-WORLD INSIGHTS IN CANCER
2
CHALLENGES
Cancer and its ComplexityDiscovering and assessing cancer therapies demands the best insights into disease etiology, treatment, impact, and outcomes. Robust analyses must account for the specific interests of all stakeholders and a variety of issues across the spectrum of cancers.
• Clinicians facing highly sophisticated treatment decisions and patient stratification
• Payers wanting more proof of value as innovations challenge stretched budgets
• Pharma generating more innovative evidence
• Patients and caregivers impacting therapeutic options
• Increasing role of advocacy groups in awareness building and data generation
3www.imshealth.com/rwe
HOLISTIC APPROACH
IMS RWE Cancer Ecosystem
Creating a common foundation of the right oncology real-world data (RWD) to address the cancer-related needs of your entire organization
IMS Health combines anonymous patient data with advanced analytics, powerful processing, and deep scientific and commercial expertise to deliver credible, breakthrough oncology insights.
4
IMS RWE CANCER ECOSYSTEM
Multi-source data representing macro-to-patient-level RWD
Comprehensive, Global Cancer Data
Innovative and client-centric technology solutions
Technology-Enabled Analytics
Delivered by a global, dedicated team, including tumor-specific specialists
Expertise-Driven Oncology Services
Unparalleled Oncology Capabilities
5www.imshealth.com/rwe
• Comprehensive cross-sectional survey data
- Coverage of 25+ primary cancers across 15+ markets
- 200,000+ patient histories per year from 4,000+ specialists
• IMS MIDAS sales data integration
• Primary data collection from specialists and patients
• Promotional data
• More than 10 years of data from 15+ million anonymous cancer patients
- EMR data
- Medical claims data
- Hospital data
- Prescription data
- Consumer data
- Biomarker and genomic alteration data
• Largest, most comprehensive cancer platform commercially available in the USA
• EMR extraction capabilities in Europe
• Predictive analytics algorithms
• Intelligent data interfaces and visualization
• Data-linking technologies designed to protect privacy
• Disease, patient, and therapy understanding
• R&D targeting and efficiency
• Market access strategies
• Real-world value demonstration, including HEOR, pharmacoepidemiology, and drug safety
• Commercial positioning, planning, and performance tracking
6
UNIQUE APPROACH TO DATA
Partnering for Richer Data to Support Precision Therapy
• Granular understanding of the comprehensive patient pathway
• Insights into differences in unmet needs, treatment use, cost, and outcomes among different genomic subpopulations
• Evaluation of targeted therapies, based on unique molecular drivers of individual cancers
The IMS Health and Foundation Medicine collaboration enables unique linkage of biomarker data with other sources of RWD such as payer claims and oncology EMR at an anonymous patient level. This provides an unprecedented evidence base for improved medical-scientific and commercialization strategies.
Biomarker Duration of Therapy
Median Days on Erlotinib Therapy (linked cohort n=152)
Source: IMS Health retrospective analysis of IMS RWD Pharmacy Prescription and Medical Claims linked to Foundation Medicine molecular profiling data
107
365
115
312
135
358
EGFR- EGFR+ EGFR+Exon
20 mut
EGFR+non-Exon
20 mut
KRAS+ KRAS-
7www.imshealth.com/rwe
CUSTOM RWD SOLUTIONS
Sourcing and Linking Expertise for T-Shaped Evidence NetworksStrategic Data Sourcing
• Enhance existing RWD through custom sourcing support to extract data and create custom datasets
• Identify and access new data sources addressing specific research needs, also in niche markets
• Benefit from IMS RWD Catalogue of 2,200+ data sources globally, including 40%+ in oncology
Data Linkage
• Understand the full patient pathway through integrating datasets at the record level (e.g., USA and Scandinavia)
• Gain deeper insights by sales indication through integration with IMS MIDAS sales data
T-Shaped Evidence Networks
Broad
Deep
Ra
ng
e o
f D
ata
Typ
es
Population Coverage
Nationally relevant databases
Augmented datasets
Biobank, labs, registries
IMS Health T-shaped Evidence Networksaddress the need to consider both breadthand depth of RWD when accessing the mostappropriate fact base
8
IMS Health has established excellence in global and local cancer-related research in mature and emerging markets.
Proven Approach: We have a track record of successful HTA submissions, published findings, and EMA-accepted Drug Utilization Studies in multiple therapy areas and geographies. Our bibliography comprises more than 3,500 publications, with 520+ in solid and liquid tumors.
Quality Systems: Our leading Quality Management System includes electronic control of standards, audit trail, and computer system validation.
Credible Solutions: Our databases and methods have been validated in peer-reviewed publications and are used by academics and authorities. They serve as part of a framework for safety assessment and for regulatory purposes.
OUR SCIENTIFIC COMMITMENT
Bringing Scientific Credibility and Quality to All Our Work
9www.imshealth.com/rwe
SERVICES
Helping StakeholdersAll functions can derive value through a shared view of what is happening in real-life healthcare settings.
• Launch pricing support
• Tumor-specific forecasting
• Ongoing value differentiation
• Launch/promotion planning
• Segmentation and targeting
• Cancer patient journeys
Commercial
• Drug utilization/monitoring
• Rigorous and efficient tumor modeling
• EMR-enabled outcomes research
• Local burden of illness/disease
• Adverse event/signal detection
• Regulatory submissions and responses
HEOR, Pharmacoepidemiology,and Drug Safety
• Custom data sourcing
• E360TM technology suite
• Evidence platforms
• T-shaped Cancer Evidence Networks
RWE Platform Developers
• Translational research
• Drug pathways
• Target population/product profile
• Trial and recruitment feasibility
R&D
10
EVIDENCE PLATFORM
IMS RWD Oncology US Platform
• More than 10 years of data from 15+ million anonymous cancer patients
Our comprehensive cancer data platform links multiple data types, including EMRs, across settings of care.
R&DPredictive
Analytics Tools
Medical-ScientificStudies/
Publications
HEORForecasting &
KOL Engagement
CommercialPatient
Analytics
Software Application(e.g., E360TM, SAS, R, Tableau)
Platform Core
Deep Clinical Data
(e.g., Genomics Data)
Enriched Data (e.g., NLP,
Linkage, Local Registry)
Broad, Nationally Relevant Databases (e.g., IMS RWD Claims Data)
Augmented Datasets (e.g., Oncology EMR)
• Data Integration• Data Hosting• Business Rules & Analytical Methods• Ongoing Data Governance
T-Shaped Portfolioof Data Sources
Services & Engagement
Technology- Enabled Analytics
Real-World Data
• Geographically representative of the USA to enable a projectable base
• Integrates biomarker, histology, consumer, and other patient datasets
11www.imshealth.com/rwe
HOW WE HELP
Enhancing RCT Results with RWE
OUR CHALLENGE
Help our client determine whether the rate and timing of hemoglobin (Hb) decline in cancer patients receiving chemotherapy seen in pooled RCT was representative of the real world.
OUR RESULTS
Our analysis verified the RCT findings, increasing payer confidence in those clinical results. This approach can help support future launch strategies when there is uncertainty regarding the applicability of RCT results to real-life settings.
OUR SOLUTION
We analyzed pooled data from six RCTs and replicated the analysis using our US community oncology clinic EMR database.
440 Patients
5,922Additional patient experiences analyzed
IMS Health Real-World Evidence SolutionsUncovering insights from real-world data to improve decision making and patient outcomes
©2016 IMS Health Incorporated and its affiliates. All rights reserved. IMS HEALTH, IMS HEALTH INTELLIGENCE APPLIED and E360 are trademarks of IMS Health Incorporated.
IMS RWD Oncology DynamicsThe latest addition to the IMS Health cross-sectional survey portfolio
CONTACT US FOR MORE INFORMATION
The Americas
One IMS Drive
Plymouth Meeting, PA 19462
USA
Tel: +1 484 567 6461
Europe
210 Pentonville Road
London, N1 9JY
United Kingdom
Tel: +44 (0) 20 3075 4800
www.imshealth.com/rwe
www.linkedin.com/company/ims-health-real-world-evidence
www.twitter.com/IMSHealthRWE
• New global study covering all key tumor types, stages, and lines of therapy
• Large physician panel with high patient sample sizes
• Facilitates understanding of cancer treatment paradigms
• Modern, web-based analytical tool to gain immediate insights
NEW IN 2016!
IMS HEALTHREAL-WORLD
EVIDENCESOLUTIONS
ALK Status
Key Cancer: Patient Count NSCLC: Line of Therapy
1st
2nd
AwaitingResults
Wild
Mutant
0 100 200 300
NSCLCCOLORECTAL
BREASTALL OTHERS
PROSTATENHL
PANCREASKIDNEY
OVARIANCLL
BLADDERCML
STOMACHSCLCAML
MELANOMA
KEY CANCER
Count (Patient-ID)
NotTested
NSCLC
3rd+
Patient ProfileIMS RWD Oncology Dynamics
https://websolutions.imshealth.com/EB2/User/CustomerLogin